Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: First Line Immunotherapy for Oesophageal and Gastric Cancer as New Standard of Care

New E-Learning module by Prof Cevantes and Dr Fleitas is now available. Watch the presentation and take the CME test today!

E-learning video block

This content is for ESMO members only.



Download slides

Learning objectives

  1. To provide an update on tumour features and immune characteristics of gastro-oesophageal adenocarcinoma and squamous oesophageal cancer ​
  2. To provide an update on findings from the studies that have recently changed the clinical practice
  3. To provide an overview of clinical studies in progress in the peri-operative setting


In this E-Learning module, the authors describe tumour features characteristics for gastro-oesophageal adenocarcinoma and squamous oesophageal cancer, immune characteristics of gastro-oesophageal adenocarcinoma and squamous oesophageal cancer. They summarise and put into clinical context the results from the studies that have recently changed the clinical practice, and provide an overview of clinical studies in progress in the peri-operative setting.

The authors emphasise that the tumour biology and the tumour immune microenvironment have an impact on the therapeutical response. They underline a new standard of care in the adjuvant setting, with immunotherapy for high-risk oesophageal and gastro-oesophageal junction adenocarcinoma, as well as chemo-immunotherapy in the first-line setting for gastro-oeshophageal adenocarcinoma with combined positive score [CPS] ≥5 and CPS≥10 in squamous cell carcinoma. They also elaborate outstanding questions, such as immune checkpoint inhibitor combinations in the peri-operative setting, new combination strategies and new biomarkers.

Through the illustration of the key tumour features and the tumour immune microenvironment shaping cancer biology and impacting on the responsiveness to therapy, the authors present findings from the clinical study of adjuvant immunotherapy for oesophageal cancer not achieving optimal remission after adjuvant chemo-radiotherapy; ongoing immunotherapy trials for localised gastro-oesophageal adenocarcinoma; key clinical studies with immune checkpoint inhibitors for advanced oeophageal squamous cell carcinoma in second- and further lines; immunotherapy in first-line for advanced oesophageal and gastro-oesophageal junction tumours; immune checkpoint inhibitors for second-line or further in gastro-oesophageal adenocarcinoma, and consider whether there is a difference in the response to immune checkpoint blockade between Asian and non-Asian populations.

A significant part of the module is dedicated to the assessment of biomarkers for immune checkpoint inhibitors in gastro-oesophageal cancer, biomarker analysis from clinical studies based on PD-L1 CPS score, the impact of MSI status on immunotherapy for oesophageal, gastro-oesophageal junction and gastric adenocarcinoma, and TMB as an immunotherapy biomarker in gastric cancer.

The authors also elaborate on the combination of targeted and immunotherapy for HER2-positive gastro-oesophageal adenocarcinoma.   

Declaration of interest

Andres Cervantes has reported:
Financial interests:
Advisory Board, Institutional: MerckSerono, Amgen, Roche, Transgene.
Invited Speaker, Institutional: Amgen, Roche, Merck Serono, Foundation Medicine.
Research Grant, Institutional, Principal Investigator: Actuate Therapeutic, Amgen, Astellas Pharma, Beigene, Bayer, AstraZeneca, BMS, Amcure, FibroGen, Lilly, Genentech, Medimmune, Merck Serono, Novartis, Natera, MSD, Servier, Sierra Oncology, Adaptimmune, Takeda.
Other, Personal, Associate Editor: Annals of Oncology, ESMO Open.
Other, Personal, Editor: Cancer Treatment Reviews.
Non-Financial Interests: 
Other, General and Scientific Director: INCLIVA  Biomedical  Research  Institute.

Tania Fleitas has reported:
Financial interests:
Servier, Invited Speaker, Personal, Update on the ongoing treatment strategies for GEA.
Bayer, Invited Speaker, Personal, The clinical impact of NRTK strategies in GI tumours.

Last update: 02 Jun 2022

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.